 KNOXVILLE, TN, Sept. 27, 2021 GLOBE NEWSWIRE -- Provectus OTCQB: PVCT today announced that data from historical clinical trials and expanded access studies of investigational cancer immunotherapy PV-10 rose bengal disodium for the single-agent treatment of Stage III melanoma NCT00521053, NCT01260779, and NCT02288897 and an ongoing clinical trial of PV-10 combination therapy for the treatment of Stage IV melanoma NCT02557321 will be presented on two poster presentations at the SMR 2021 Congress the Society for Melanoma Research annual meeting to be held online from October 28-31. 